The Conversation (0)
XORTX Therapeutics (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the development of treatments for progressive kidney disease, including polycystic kidney disease and rare diseases such as autosomal dominant polycystic kidney disease. As quoted in the press release: At the present time, despite considerable effort, very …
XORTX Therapeutics (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the development of treatments for progressive kidney disease, including polycystic kidney disease and rare diseases such as autosomal dominant polycystic kidney disease.
As quoted in the press release:
At the present time, despite considerable effort, very few approved therapeutic options exist to treat progressive kidney disease. There is reason for hope, however. Based on recent clinical study evidence, the presence of uric acid above the normal range can act to negatively affect the health and therapeutic outcomes of patients with PKD. The PKD Foundation is supportive of new treatments to lower and maintain uric acid levels in patients. Towards this goal, the PKD Foundation will make available its scientific expertise to support and collaborate with XORTX to discover these new treatments.
Dr. David Baron, Chief Scientific Officer, PKD Foundation stated, “We believe that the combination of the PKD Foundation’s and XORTX’s scientific expertise may enable an entirely new class of highly active and potentially important treatments for patients for whom current biopharmaceutical approaches have had limited success.”
